Thomas Ciulla - 03 Jan 2024 Form 3 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Medical Officer
Signature
/s/ Thomas Ciulla
Issuer symbol
VRDN
Transactions as of
03 Jan 2024
Net transactions value
$0
Form type
3
Filing time
12 Jan 2024, 16:31:56 UTC
Previous filing
20 Jan 2023
Next filing
07 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VRDN Common Stock 762 03 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VRDN Stock Option (Right to Buy) 03 Jan 2024 Common Stock 250,000 $33.06 Direct F1
holding VRDN Stock Option (Right to Buy) 03 Jan 2024 Common Stock 50,000 $28.22 Direct F2
holding VRDN Stock Option (Right to Buy) 03 Jan 2024 Common Stock 270,000 $13.76 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which will vest on February 17, 2024, with the remaining vesting in approximately equal monthly installments through February 17, 2027, subject to the Reporting Person's continued service to the Issuer.
F2 This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 8,333 of which have vested, with the remaining vesting in approximately equal monthly installments through April 25, 2027, subject to the Reporting Person's continued service to the Issuer.
F3 This option represents a right to purchase a total of 270,000 shares of the Issuer's common stock, 11,250 of which have vested, with the remaining vesting in approximately equal monthly installments through November 10, 2027, subject to the Reporting Person's continued service to the Issuer.